Quarterly loss decreases for ProQR

ProQR Therapeutics reported a net loss of 6 million euros, or 0.18 euros per share, in the third quarter of 2018 compared with a net loss of 10.5 million euros, or 0.42 euros per share, in the previous year’s third quarter.
Research and development costs totaled 6.3 million euros compared with 7.2 million euros in 2017’s third quarter, while general and administrative costs decreased from 2.8 million euros to 2.6 million euros.
The company had cash and cash equivalents of 113.7 million euros as of Sept. 30 due to the (Read more...)

Full Story →